Recombinant human coagulation factor VIII-Fc fusion protein(Haimen Gensciences)
重组人凝血因子VIII-Fc融合蛋白（海门晟斯）
Report date: 2026/05/28 20:00:21
Base Information
Drug NameRecombinant human coagulation factor VIII-Fc fusion protein(Haimen Gensciences)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications +[5]
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesJiangsu Gensciences lnc
China Registration ClassClass 1 therapeutic biologic in China
Develop Information
Active CompaniesZhengzhou Gensciences Biotechnology Co LtdJiangsu Gensciences lncBeijing Furen Ruihui Biomedical Research Institute Co Ltd +[5]
Inactive CompaniesN/A
Active Indications +[5]
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A